DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Raltegravir and Atazanavir Dosing Strategy Study

Information source: Kirby Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HIV Infection

Intervention: atazanavir plus raltegravir (Drug); atazanavir plus raltegravir (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Kirby Institute

Official(s) and/or principal investigator(s):
David A Cooper, MD DSc, Principal Investigator, Affiliation: Kirby Institute/UNSW

Summary

To compare the steady-state pharmacokinetics and short-term efficacy and safety of two dosing strategies of raltegravir and atazanavir in virologically suppressed HIV-infected adults receiving atazanavir-containing combination antiretroviral therapy.

Clinical Details

Official title: A Randomised, Open-label, Cross-over Study to Examine the Pharmacokinetics and Short-term Safety and Efficacy of Two Dosing Strategies of Raltegravir Plus Atazanavir in HIV-infected Patients

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: comparison of the mean steady-state atazanavir trough plasma concentrations for once (C24) and twice (C12) daily dosing strategies

Secondary outcome:

comparison of mean steady-state raltegravir trough plasma concentrations for once (C24) and twice (C12) daily dosing

comparison of steady-state pharmacokinetic profiles of once and twice-daily atazanavir

comparison of the steady-state pharmacokinetic profiles of once and twice-daily raltegravir

change from baseline in fasting lipid and glycaemic parameters

change from baseline in CD4+ T-lymphocyte count

change from baseline in HIV-RNA

all adverse events attributable to study treatment

all serious, grade 3 or 4 clinical adverse events, and any adverse event leading to premature cessation of study treatment

Detailed description: Current HIV treatment guidelines recommend the construction of combination regimens comprising a minimum of three agents from at least two drug classes. There are problems with the current recommendations for although treatments are effective, their success is often limited by tolerability, adverse effects and the need to take many pills. Antiretroviral adherence remains vital and regimens should be simplified wherever possible to facilitate maximal adherence. The recent availability of the potent HIV integrase inhibitor, raltegravir, provides an opportunity to explore moves away from current regimen components. Evidence to support the use of novel regimens must be generated through adequately powered randomized clinical trials. However, before such trials can be undertaken, preliminary data to define the pharmacokinetics, safety and tolerability of these regimens are needed to minimize unnecessary risk for participants. This eight week study will investigate the steady-state pharmacokinetics, and short-term safety and efficacy of two dosing strategies (once and twice daily) of raltegravir plus atazanavir in treatment experienced HIV-infected adults.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- aged ≥ 18 years with laboratory evidence of HIV-1 infection

- currently receiving 3 or more unchanged antiretroviral agents including atazanavir

(with or without ritonavir boosting) for at least 24 weeks prior to study entry

- plasma HIV RNA less than 50 copies/mL for at least 24 weeks prior to study entry

- provide written, informed consent.

Exclusion Criteria :

- prior clinical/virological failure on a PI-containing regimen

- no clinical history of primary HIV-1 protease mutations identified in local baseline

genotypic analysis of HIV with interpretation using current IAS-USA Drug Resistance Mutations in HIV-1

- women: pregnant, breastfeeding, or not willing to use adequate contraception

(including barrier contraception) if of child-bearing potential

- laboratory abnormalities at screening:

- absolute neutrophil count (ANC) < 750 cells/mL

- haemoglobin less than 8. 5 g/dL

- platelet count less than 50 000 cells/mL

- AST, ALT > 5 times the upper limit of normal

- serum bilirubin > 5 times the upper limit of normal

- chronic active hepatitis B infection defined by presence of serum viral hepatitis B

surface antigen (HBsAg) or HBV DNA-positive

- any malabsorption syndrome likely to affect drug absorption

- concurrent therapy with human growth hormone or other immunomodulatory agents

- concomitant medication contraindicated for use with either atazanavir or raltegravir

therapy

- any inter-current illness requiring hospitalisation

- current excessive alcohol or illicit substance use

- unlikely to be able to remain in follow-up for the protocol-defined period.

Locations and Contacts

Holdsworth House Medical Practice, Sydney, New South Wales 2010, Australia

St Vincent's Hospital, Sydney, New South Wales 2010, Australia

Additional Information

Starting date: July 2009
Last updated: April 10, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017